In this article, we will list the 5 Best Small-Cap Value Stocks to Buy. Please visit 10 Best Small-Cap Value Stocks to Buy if you would like to see the extended list and the methodology behind it.
5. Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY)
Forward P/E: 9.65
Market Cap: $1.87 Billion
Number of Hedge Fund Holders: 37
Stock Upside Potential: 37.45%
Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) is one of the best small-cap value stocks to buy. On April 24, H.C. Wainwright reiterated a Buy rating on Harmony Biosciences Holdings Inc. (NASDAQ:HRMY) and a $55 price target.
The bullish stance is in response to positive discussions with the company’s senior management, including President and CEO Jeff Dayno, newly appointed CFO Glenn Reicin, and Head of Investor Relations Brennan Doyle. The discussions centered on patent infringement claims against AET Pharma and Sandoz.
The patent in question covers new pitolisant formulations that expand IP protection for WAKIX beyond its pure crystalline polymorph formulation. Harmony Biosciences has already granted Novitum Pharma an exclusive license to manufacture its generic version of pitolisant, including an amorphous formulation.
Analysts at Oppenheimer have already raised Harmony Biosciences’ price target to $72 while maintaining an outperform rating, buoyed by the company’s strong patent portfolio. The company is also accelerating the development of Clemizole Hydrochloride (EPX-100) for the treatment of Dravet Syndrome and Lennox-Gastaut Syndrome.
Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) is a commercial-stage pharmaceutical company focused on developing and commercializing therapies for patients with rare neurological diseases. Their primary product is WAKIX (pitolisant), a first-in-class medicine approved by the FDA for the treatment of excessive daytime sleepiness or cataplexy in adult patients with narcolepsy.
4. ANI Pharmaceuticals, Inc. (NASDAQ:ANIP)
Forward P/E: 9.12
Market Cap: $1.93 Billion
Number of Hedge Fund Holders: 41
Stock Upside Potential: 43.30%
ANI Pharmaceuticals, Inc. (NASDAQ:ANIP)is one of the best small-cap value stocks to buy. On April 20, ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) confirmed the Food and Drug Administration’s approval of Pimozide Tablets in 1 mg and 2 mg strengths.
Following approval, the company has launched Pimozide tablets, a generic version of the reference listed drug (RLD) Orap. The company has also successfully secured 180-day CGT exclusivity for the drug.
The launch underscores Ani Pharmaceuticals’ focus on bringing to market products with limited competition while offering generic alternatives to customers. Pimozide annual sales in the US total about $3.1 million
The launch of Pimozide tablets comes against the backdrop of the company’s launch of Carbamazepine Extended-Release Capsules in 100 mg, 200 mg, and 300 mg strengths. The launch of the generic version of RLD Carbatrol continues to strengthen the company’s generic portfolio. U.S. annual sales for Carbamazepine Extended-Release Capsules total approximately $65 million.
ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) is a diversified biopharmaceutical company that develops, manufactures, and commercializes high-quality branded, generic, and over-the-counter pharmaceuticals. They focus on rare diseases (ophthalmology, oncology) and maintain U.S.-based manufacturing facilities, including specialized capabilities for potent, high-containment products.
3. Globant S.A. (NYSE:GLOB)
Forward P/E: 6.47
Market Cap: $1.73 Billion
Number of Hedge Fund Holders: 33
Stock Upside Potential: 55.51%
Globant S.A. (NYSE: GLOB) is one of the best small-cap value stocks to buy. On April 9, analysts at Wedbush initiated coverage of Globant S.A. (NYSE: GLOB) with an Outperform rating and a $61 price target. According to the research firm, IT services continue to play an integral part in cloud computing.
The research firm remains bullish about Globant’s prospects, as the use of AI technologies remains a key enabler of the next stage of operational advancement. It also expects the company to benefit as spending on IT projects begins to recover after slowing during the pandemic. The improvement would come as global enterprises pursue AI-driven strategies.
The sentiments come as the company has been named as an Autodesk Tandem Digital Twin Solution Provider, expanding a 15-year collaboration with Autodesk. Consequently, the company is to deliver implementation services, enterprise system integrations, and operational data enablement. It is also expected to accelerate the implementation of digital twins across airports, smart buildings, and logistics environments.
Globant S.A. (NYSE:GLOB) is a digitally native IT and software development company focused on digital transformation and AI-driven solutions. It helps organizations reinvent their businesses through services such as AI integration, software development, and experiential marketing across media, finance, healthcare, and gaming.
2. Innoviva, Inc. (NASDAQ:INVA)
Forward P/E: 11.95
Market Cap: $1.68 Billion
Number of Hedge Fund Holders: 29
Stock Upside Potential: 60.10%
Innoviva, Inc. (NASDAQ:INVA) is one of the best small-cap value stocks to buy. On April 8 , Cantor Fitzgerald reiterated an Overweight rating on Innoviva Inc. (NASDAQ:INVA) and a $32 price target. The research firm remains confident about the company’s prospects, owing to the stability of its recurring royalty business that generated about $250 million in 2025.
The research firm expects the royalty recurring business to provide significant stock protection. That’s in part because the company is increasingly investing to grow the royalty revenue base in the Specialty Therapeutics segment. The segment boasts $175 million in trailing-12-month revenue.
Innoviva also owns a large equity stake of about 70% in Armata Pharmaceuticals, which is also expected to drive long-term growth and differentiation. The company also remains well capitalized, with multiple value-accretive capital deployment opportunities across the current business, novel assets, and capital strategies.
Innoviva, Inc. (NASDAQ:INVA) is a diversified holding company that manages a portfolio of biopharmaceutical royalties and invests in, develops, and commercializes healthcare assets. Its core business focuses on royalties from respiratory products (RELVAR®/BREO® and ANORO® ELLIPTA®) partnered with GSK, alongside a specialized therapeutic platform, Innoviva Specialty Therapeutics, focused on critical care and infectious diseases.
1. Magnite Inc. (NASDAQ:MGNI)
Forward P/E: 14.14
Market Cap: $1.95 Billion
Number of Hedge Fund Holders: 41
Stock Upside Potential: 75.74%
Magnite Inc. (NASDAQ:MGNI) is one of the best small-cap value stocks to buy. On April 28, analysts at Benchmark reiterated a Buy rating on Magnite Inc. (NASDAQ:MGNI) with a $30 price target. The positive stance underscores the research firm’s confidence about the company’s position in the connected television advertising market.
Additionally, the research firm has echoed the potential impact of Magnite working with Walmart and Amazon to monetize its off-platform advertising. The company also works with more than 10 commerce media players, as well as internet and audio companies, which are expected to strengthen its advertising prospects.
Magnite expects its CTV revenue, excluding traffic acquisition costs, to grow by more than 30% in the near term. The robust growth would also come from the company expanding its AI capabilities across the advertising platform.
The integration is expected to enhance the SpringServe video platform that features demand path optimization. It has also inked a strategic partnership with Nova Entertainment, which provides programmatic advertising in Australia.
Magnite Inc. (NASDAQ:MGNI) is the world’s largest independent sell-side advertising platform (SSP). It enables digital publishers and media owners to sell ad space across CTV, desktop, mobile, and audio in real time. Magnite helps clients manage inventory, monetize, and automate transactions, including for premium video streaming services.
While we acknowledge the potential of MGNI to grow, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than MGNI and that has 100x upside potential, check out our report about the cheapest AI stock.
READ NEXT: 10 Most Oversold Canadian Stocks to Invest In and 10 Best Stocks to Buy in 2026 According to Billionaire George Soros.
Disclosure: None. Insider Monkey focuses on uncovering the best investment ideas of hedge funds and insiders. Please subscribe to our free daily e-newsletter to get the latest investment ideas from hedge funds’ investor letters by entering your email below.
